NL-OMON23674
Completed
Not Applicable
Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists
Ron J.G. Peters, MDDepartment of CardiologyF3-236Academic Medical CenterP.O. Box 226601100 DD AmsterdamThe Netherlandsphone +31 20 5666952fax +31 20 5669747Email r.j.peters@amc.uva.nl0 sites1,000 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Coronary Syndrome, Preventive cardiology, Secondary Prevention of Cardiovasculair disease, Nurse SpecialistsAcuut coronair syndroom, Preventieve Cardiologie, Secundaire Preventie van hart- en vaatziekten, Gespecialiceerde verpleegkundigen
- Sponsor
- Ron J.G. Peters, MDDepartment of CardiologyF3-236Academic Medical CenterP.O. Box 226601100 DD AmsterdamThe Netherlandsphone +31 20 5666952fax +31 20 5669747Email r.j.peters@amc.uva.nl
- Enrollment
- 1000
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients between 18\-80 years hospitalised less than 8 weeks before inclusion for an acute coronary syndrome, either unstable angina or acute myocardial infarction, will be included
Exclusion Criteria
- •Patients will be excluded if clinic visits are not feasible, if not available for follow\-up, if surgery, percutaneous coronary intervention or other interventions are expected within 8 weeks, if life expectancy is considered limited, if previously enrolled in NLPC or if NYHA class 3 or 4 from heart failure.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialistsNL-OMON30357Academisch Medisch Centrum1,000
Completed
Phase 4
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)HIV InfectionNCT01576731Hospital Clinic of Barcelona240
Completed
Phase 4
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)HIV InfectionNCT01533272Hospital Clinic of Barcelona240
Not yet recruiting
Phase 2
Phase II study to evaluate the preventive effect and safety of lubiprostone in opioid-induced constipatiocancer painJPRN-jRCTs051230150Kuriyama Toshiyuki37
Not yet recruiting
Not Applicable
A comparative study assessing the secondary prevention efficacy between center-based vs. home-based cardiact rehabilitation in patients with cardiovascular diseasesDiseases of the circulatory systemKCT0006385Ewha Womans University Medical Center1,040